All Stories

  1. médecine/sciences 2018, une revue au coeur des débats et défis actuels et à venir de la recherche

    Article • médecine/sciences, January 2018, EDP Sciences

    Dr Jean-Luc Teillaud

  2. médecine/sciences 2017 : the French touch des avancées des connaissances biomédicales en… langue française

    Article • médecine/sciences, January 2017, EDP Sciences

    Dr Jean-Luc Teillaud

  3. Le mot des coordinateurs

    Article • médecine/sciences, November 2016, EDP Sciences

    Dr Jean-Luc Teillaud

  4. L’homme qui a fait sauter le verrou de la réponse immune adaptative anti-tumorale

    Article • médecine/sciences, January 2016, EDP Sciences

    Dr Jean-Luc Teillaud

  5. Quand les anticorps rencontrent l’immunité antitumorale : fin de partie pour la cellule cancéreuse ?

    Article • médecine/sciences, August 2015, EDP Sciences

    Dr Jean-Luc Teillaud

  6. Les années 2010

    Article • médecine/sciences, March 2015, EDP Sciences

    Dr Jean-Luc Teillaud, Dr Herve Chneiweiss

  7. Abstract 3636: Anti-CD20 therapy prevents protumor regulatory T-cell expansion and triggers a memory Th1 response in tumor-bearing mice

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Dr Jean-Luc Teillaud

  8. Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice

    Article • Leukemia, September 2014, Nature

    Dr Jean-Luc Teillaud

  9. The vaccinal effect of monoclonal antibodies in cancer therapy

    Article • May 2014, Oxford University Press (OUP)

    Dr Jean-Luc Teillaud

  10. Microenvironnements tumoraux : conflictuels et complémentaires

    Article • médecine/sciences, April 2014, EDP Sciences

    Dr Jean-Luc Teillaud

  11. Natural Autoantibodies to Fcγ Receptors in Intravenous Immunoglobulins

    Article • Journal of Clinical Immunology, April 2014, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  12. Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer

    Article • American Review of Respiratory Disease, April 2014, American Thoracic Society

    Dr Jean-Luc Teillaud

  13. Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells

    Article • Molecular Cancer Therapeutics, June 2013, American Association for Cancer Research (AACR)

    Dr Jean-Luc Teillaud

  14. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

    Article • Mucosal Immunology, April 2013, Nature

    Dr Jean-Luc Teillaud

  15. Le double visage des anticorps monoclonaux en oncologie

    Article • médecine/sciences, January 2013, EDP Sciences

    Dr Jean-Luc Teillaud

  16. Antibody-dependent Cellular Cytotoxicity (ADCC)

    Article • July 2012, Wiley

    Dr Jean-Luc Teillaud

  17. Human Macrophages and Dendritic Cells Can Equally Present MART-1 Antigen to CD8+ T Cells after Phagocytosis of Gamma-Irradiated Melanoma Cells

    Article • PLoS ONE, July 2012, PLOS

    Dr Jean-Luc Teillaud

  18. 1st French-Israeli International Conference on B Cells and therapeutic antibodies

    Article • mAbs, July 2012, Taylor & Francis

    Dr Jean-Luc Teillaud

  19. High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function

    Article • Medical Oncology, June 2012, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  20. Effect of zinc on human IgG1 and its FcγR interactions

    Article • Immunology Letters, March 2012, Elsevier

    Dr Jean-Luc Teillaud

  21. Crystal structure of monoclonal human anti-rhesus D Fc IgG1 t125(yb2/0) double mutant (H310 and H435 in K)

    Article • February 2012, Protein Data Bank, Rutgers University

    Dr Jean-Luc Teillaud

  22. Crystal structure of monoclonal human anti-Rhesus D Fc IgG1 T125(YB2/0) in the presence of Zn2+

    Article • February 2012, Protein Data Bank, Rutgers University

    Dr Jean-Luc Teillaud

  23. Crystal structure of monoclonal human anti-rhesus D Fc and IgG1 t125(yb2/0) in the presence of EDTA

    Article • February 2012, Protein Data Bank, Rutgers University

    Dr Jean-Luc Teillaud

  24. From Whole Monoclonal Antibodies to Single Domain Antibodies: Think Small

    Article • January 2012, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  25. Immunothérapie et anticorps monoclonaux

    Article • médecine/sciences, January 2012, EDP Sciences

    Dr Jean-Luc Teillaud

  26. À propos de Ralph M. Steinman et des cellules dendritiques

    Article • médecine/sciences, November 2011, EDP Sciences

    Dr Jean-Luc Teillaud

  27. A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms

    Article • PLoS ONE, October 2011, PLOS

    Dr Jean-Luc Teillaud

  28. CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells

    Article • Vaccine, March 2011, Elsevier

    Dr Jean-Luc Teillaud

  29. IBC's 21stAnnual Antibody Engineering and 8thAnnual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society

    Article • mAbs, March 2011, Taylor & Francis

    Dr Jean-Luc Teillaud

  30. Modulation of tumor immunity by therapeutic monoclonal antibodies

    Article • Cancer and Metastasis Reviews, January 2011, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  31. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

    Article • Leukemia, October 2010, Nature

    Dr Jean-Luc Teillaud

  32. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

    Article • Journal of Crohn s and Colitis, October 2010, Oxford University Press (OUP)

    Dr Jean-Luc Teillaud

  33. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

    Article • Blood, May 2010, American Society of Hematology

    Dr Jean-Luc Teillaud

  34. Impact of Glycosylation on Effector Functions of Therapeutic IgG

    Article • Pharmaceuticals, January 2010, MDPI AG

    Dr Jean-Luc Teillaud

  35. Une histoire de fusion… réussie et non brevetée : les anticorps monoclonaux

    Article • médecine/sciences, December 2009, EDP Sciences

    Dr Jean-Luc Teillaud

  36. Le mot des coordinateurs

    Article • médecine/sciences, December 2009, EDP Sciences

    Dr Jean-Luc Teillaud

  37. Les anticorps : mieux les connaître pour mieux s’en servir

    Article • médecine/sciences, December 2009, EDP Sciences

    Dr Jean-Luc Teillaud

  38. Les anticorps EMABling®

    Article • médecine/sciences, December 2009, EDP Sciences

    Dr Jean-Luc Teillaud

  39. Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target

    Article • Expert Review of Clinical Immunology, November 2009, Taylor & Francis

    Dr Jean-Luc Teillaud

  40. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen

    Article • European Journal of Biochemistry, July 2009, Wiley

    Dr Jean-Luc Teillaud

  41. Qu’est-ce qu’une biothérapie ? L’exemple des anticorps monoclonaux

    Article • La Presse Médicale, May 2009, Elsevier

    Dr Jean-Luc Teillaud

  42. Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fc RIIB

    Article • The Journal of Immunology, October 2008, The American Association of Immunologists

    Dr Jean-Luc Teillaud

  43. Immune control of tumors: host immune response and antibody-based immunotherapy

    Article • Biomedicine & Pharmacotherapy, October 2008, Elsevier

    Dr Jean-Luc Teillaud

  44. A novel subset of NK cells expressing high levels of inhibitory Fc RIIB modulating antibody-dependent function

    Article • Journal of Leukocyte Biology, September 2008, Society for Leukocyte Biology

    Dr Jean-Luc Teillaud

  45. Increased levels of soluble low-affinity Feγ receptors (IgG-binding factors) in the sera of tumour-bearing mice

    Article • Clinical & Experimental Immunology, June 2008, Wiley

    Dr Jean-Luc Teillaud

  46. A human anti-D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies

    Article • British Journal of Haematology, April 2008, Wiley

    Dr Jean-Luc Teillaud

  47. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

    Article • British Journal of Haematology, March 2008, Wiley

    Dr Jean-Luc Teillaud

  48. Isolation and characterization of anti-Fc RIII (CD16) llama single-domain antibodies that activate natural killer cells

    Article • Protein Engineering Design and Selection, December 2007, Oxford University Press (OUP)

    Dr Jean-Luc Teillaud

  49. FcγR: The key to optimize therapeutic antibodies?

    Article • Critical Reviews in Oncology/Hematology, April 2007, Elsevier

    Dr Jean-Luc Teillaud

  50. Molecular aspects of human FcγR interactions with IgG: Functional and therapeutic consequences

    Article • Immunology Letters, August 2006, Elsevier

    Dr Jean-Luc Teillaud

  51. Anticorps monoclonaux : tours et détours technologiques pour de nouveaux espoirs thérapeutiques

    Article • Comptes Rendus Biologies, April 2006, Elsevier

    Dr Jean-Luc Teillaud

  52. Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions

    Article • Clinical Immunology, February 2006, Elsevier

    Dr Jean-Luc Teillaud

  53. Le deuxième acte des anticorps monoclonaux : de nouvelles molécules pour de nouveaux défis

    Article • Journal de la Société de Biologie, January 2006, EDP Sciences

    Dr Jean-Luc Teillaud

  54. CD16b associates with high-density, detergent-resistant membranes in human neutrophils

    Article • Biochemical Journal, January 2006, Portland Press Ltd.

    Dr Jean-Luc Teillaud

  55. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges

    Article • Expert Opinion on Biological Therapy, September 2005, Informa Healthcare

    Dr Jean-Luc Teillaud

  56. Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes

    Article • The Journal of Immunology, August 2005, The American Association of Immunologists

    Dr Jean-Luc Teillaud

  57. Anticorps monoclonaux à usage thérapeutique : un peu d'histoire, beaucoup d'ingénierie, et … quelques succès cliniques

    Article • Transfusion Clinique et Biologique, June 2005, Elsevier

    Dr Jean-Luc Teillaud

  58. Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma

    Article • Pathology & Oncology Research, June 2005, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  59. Dossier: Auto-immunity and Biotherapy

    Article • Biomedicine & Pharmacotherapy, June 2004, Elsevier

    Dr Jean-Luc Teillaud

  60. Dossier: Auto-immunity and Biotherapy

    Article • Biomedicine & Pharmacotherapy, May 2004, Elsevier

    Dr Jean-Luc Teillaud

  61. Imaging capabilities of synchrotron infrared microspectroscopy

    Article • Faraday Discussions, January 2004, Royal Society of Chemistry

    Dr Jean-Luc Teillaud

  62. Future Prospects in Antibody Engineering and Therapy

    Article • January 2004, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  63. Expression of Recombinant Antibodies by Tumour Cells: On Road to Anti-Tumour Therapy

    Article • January 2004, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  64. Fcγ Receptor-like Activity of Hepatitis C Virus Core Protein

    Article • Journal of Biological Chemistry, November 2003, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Jean-Luc Teillaud

  65. Chemical heterogeneity in cell death: Combined synchrotron IR and fluorescence microscopy studies of single apoptotic and necrotic cells

    Article • Biopolymers, January 2003, Wiley

    Dr Jean-Luc Teillaud

  66. Combining IR spectroscopy with fluorescence imaging in a single microscope: Biomedical applications using a synchrotron infrared source (invited)

    Article • Review of Scientific Instruments, March 2002, American Institute of Physics

    Dr Jean-Luc Teillaud

  67. Regulated Expression and Inhibitory Function of Fc RIIb in Human Monocytic Cells

    Article • Journal of Biological Chemistry, December 2001, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Jean-Luc Teillaud

  68. Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcγR scFv on cancer cell surface

    Article • Gene Therapy, November 2001, Nature

    Dr Jean-Luc Teillaud

  69. Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use

    Article • British Journal of Haematology, September 2001, Wiley

    Dr Jean-Luc Teillaud

  70. The Fc Receptor for IgG Expressed in the Villus Endothelium of Human Placenta Is Fc RIIb2

    Article • The Journal of Immunology, March 2001, The American Association of Immunologists

    Dr Jean-Luc Teillaud

  71. PURIFICATION OF SOLUBLE RECOMBINANT HUMAN FcγRII (CD32)

    Article • Preparative Biochemistry & Biotechnology, January 2001, Taylor & Francis

    Dr Jean-Luc Teillaud

  72. Differential Modulation of Stimulatory and Inhibitory Fc  Receptors on Human Monocytes by Th1 and Th2 Cytokines

    Article • The Journal of Immunology, January 2001, The American Association of Immunologists

    Dr Jean-Luc Teillaud

  73. Anticorps monoclonaux: la nouvelle vague

    Article • Biofutur, February 2000, Elsevier

    Dr Jean-Luc Teillaud

  74. A scFv Phage Display Mini Library Generated from the Immunoglobulin Repertoire of Breast Medullary Carcinoma Infiltrating B Lymphocytes

    Article • Disease Markers, January 2000, Hindawi Publishing Corporation

    Dr Jean-Luc Teillaud

  75. Ras and p53 Intracellular Targeting with Recombinant Single-Chain Fv (scFv) Fragments: A Novel Approach for Cancer Therapy?

    Article • Cancer Detection and Prevention, November 1999, Wiley

    Dr Jean-Luc Teillaud

  76. Vav and SLP-76 recruitment by cross-linking of FcγRIIa1 in promyelocytic HL-60 cells

    Article • Immunology Letters, June 1999, Elsevier

    Dr Jean-Luc Teillaud

  77. Recherche de qualité et qualité de la recherche

    Article • Biofutur, April 1999, Elsevier

    Dr Jean-Luc Teillaud

  78. Generation of phagocytic MAK and MAC-DC for therapeutic use

    Article • Experimental Hematology, April 1999, Elsevier

    Dr Jean-Luc Teillaud

  79. Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma

    Article • Immunology Letters, February 1999, Elsevier

    Dr Jean-Luc Teillaud

  80. A tumor specific single chain antibody dependent gene expression system

    Article • Oncogene, January 1999, Nature

    Dr Jean-Luc Teillaud

  81. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments

    Article • Oncogene, January 1999, Nature

    Dr Jean-Luc Teillaud

  82. Soluble CD16 in Plasma Cell Dyscrasias

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Jean-Luc Teillaud

  83. Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific λ and irrelevant κ light chains

    Article • Molecular Immunology, December 1998, Elsevier

    Dr Jean-Luc Teillaud

  84. Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation

    Article • Biomedicine & Pharmacotherapy, July 1998, Elsevier

    Dr Jean-Luc Teillaud

  85. Highly resolved chemical imaging of living cells by using synchrotron infrared microspectrometry

    Article • Proceedings of the National Academy of Sciences, April 1998, Proceedings of the National Academy of Sciences

    Dr Jean-Luc Teillaud

  86. In vivo induction of functional FcγRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF)

    Article • British Journal of Haematology, March 1998, Wiley

    Dr Jean-Luc Teillaud

  87. Soluble FcγR, a biological perspective

    Article • January 1998, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  88. Intracellular Targeting of Oncogenes: A Novel Approach for Cancer Therapy

    Article • January 1998, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  89. A New Set of Monoclonal Antibodies Against Human FcγRII (CD32) and FcγRIII (CD16): Characterization and Use in Various Assays

    Article • Hybridoma, December 1997, Mary Ann Liebert Inc

    Dr Jean-Luc Teillaud

  90. Chemical imaging of living cells by synchrotron infrared microspectrometry

    Article • October 1997, SPIE

    Dr Jean-Luc Teillaud

  91. Production and Characterization of Mouse Monoclonal Antibodies to Wild-Type and Oncogenic FLI-1 Proteins

    Article • Hybridoma, October 1997, Mary Ann Liebert Inc

    Dr Jean-Luc Teillaud

  92. Generation and Characterization of a Mouse Single-Chain Antibody Fragment Specific for Disialoganglioside (G D2 )

    Article • Hybridoma, August 1997, Mary Ann Liebert Inc

    Dr Jean-Luc Teillaud

  93. Antlcorp mon clonaux: le grand retour

    Article • Biofutur, June 1997, Elsevier

    Dr Jean-Luc Teillaud

  94. Phage display and antibody engineering: a french overview

    Article • Trends in Biotechnology, May 1997, Elsevier

    Regis Sodoyer, Dr Jean-Luc Teillaud

  95. Immunoglobulin variable regions usage by B lymphocytes infiltrating human breast medullary carcinoma

    Article • Immunology Letters, May 1997, Elsevier

    Dr Jean-Luc Teillaud

  96. Transformer le monde pour en faire le meilleur des mondes?

    Article • Biofutur, April 1997, Elsevier

    Dr Jean-Luc Teillaud

  97. Fc Receptors and Pathology

    Article • January 1997, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  98. Fc Receptors as Targets for Immunotherapy

    Article • International Reviews of Immunology, January 1997, Taylor & Francis

    Dr Jean-Luc Teillaud

  99. Functions of Fc Receptors on Human Dendritic Langerhans Cells

    Article • International Reviews of Immunology, January 1997, Taylor & Francis

    Dr Jean-Luc Teillaud

  100. Soluble Fcγ Receptor, FcγRIIa2, is Present in Two Forms in Human Serum and is Increased in Patients: With Stage C Chronic Lymphocytic Leukemia

    Article • Leukemia & Lymphoma, January 1997, Taylor & Francis

    Dr Jean-Luc Teillaud

  101. Le nouveau look des anticorps

    Article • Biofutur, May 1996, Elsevier

    Regis Sodoyer, Dr Jean-Luc Teillaud

  102. Epitope Mapping and Tight-Binding Inhibition with Monoclonal Antibodies Directed againstEscherichia coliGlucosamine 6-phosphate Synthase

    Article • Archives of Biochemistry and Biophysics, December 1995, Elsevier

    Dr Jean-Luc Teillaud

  103. Prognostic value of cytokine and soluble Fcγ receptor assays in oncology

    Article • Immunology Letters, January 1995, Elsevier

    Dr Jean-Luc Teillaud

  104. In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-FcγRI (CD64) bispecific antibody

    Article • European Journal of Cancer, January 1995, Elsevier

    Dr Jean-Luc Teillaud

  105. Natural and Recombinant Soluble Low-Affinity FcγR: Detection, Purification, and Functional Activities

    Article • ImmunoMethods, February 1994, Elsevier

    Dr Jean-Luc Teillaud

  106. Detection and quantification of secreted soluble FcγRIIA in human sera by an enzyme-linked immunosorbent assay

    Article • Journal of Immunological Methods, November 1993, Elsevier

    Dr Jean-Luc Teillaud

  107. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura

    Article • The Lancet, October 1993, Elsevier

    Dr Jean-Luc Teillaud

  108. Effects of low dose total body irradiation (LDTBI) and recombinant human interleukin-2 in mice

    Article • Radiotherapy and Oncology, March 1993, Elsevier

    Dr Jean-Luc Teillaud

  109. Corrélation entre le taux sérique du CD16 soluble et le stade du myélome: étude de 214 sérums

    Article • La Revue de Médecine Interne, January 1993, Elsevier

    Dr Jean-Luc Teillaud

  110. Differential Effects of Low Doses Of Structurally Different Anthracyclines on Immunoglobulin Production by Mouse Hybridoma B Cells

    Article • January 1993, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  111. Structures Involved in the Activities of Murine Low Affinity Fcγ Receptors (FcγR)

    Article • January 1993, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  112. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma

    Article • Journal of Clinical Immunology, January 1993, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  113. Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (Fc γ R) encoded by an alternatively spliced transcript of the Fc γ RII gene

    Article • International Immunology, January 1993, Oxford University Press (OUP)

    Dr Jean-Luc Teillaud

  114. Murine soluble Fcγ receptors/IgG-binding factors (IgG-BF): Analysis of the relation to FcγRII and production of milligram quantities of biologically active recombinant IgG-BF

    Article • Immunologic Research, December 1992, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  115. In vitro inhibition of tumor B cell growth by IgG-BF-producing FcγRII+T cell hybridoma and by immunoglobulin G-binding factors

    Article • Immunologic Research, December 1992, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  116. Release of Soluble FcgammaRII/CD32 Molecules by Human Langerhans Cells: A Subtle Balance Between Shedding and Secretion?

    Article • Journal of Investigative Dermatology, November 1992, Elsevier

    Dr Jean-Luc Teillaud

  117. Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid FcγRII Expressing Tumor Cells

    Article • Immunobiology, August 1992, Elsevier

    Dr Jean-Luc Teillaud

  118. Soluble FcγR (sFcγR): Detection in Biological Fluids and Production of a Murine Recombinant sFcγR Biologically Active in vitro and in vivo

    Article • Immunobiology, August 1992, Elsevier

    Dr Jean-Luc Teillaud

  119. Monoclonal Antibodies Against Bacterial Glucosamine 6-Phosphate Synthase: Production and Use for Structural Studies

    Article • Hybridoma, April 1992, Mary Ann Liebert Inc

    Dr Jean-Luc Teillaud

  120. Structural Bases of Fcgamma Receptor Functions

    Article • Immunological Reviews, February 1992, Wiley

    Dr Jean-Luc Teillaud

  121. Evaluation of circulating tumor necrosis factor-α in patients with gynecological malignancies

    Article • International Journal of Cancer, May 1991, Wiley

    Dr Jean-Luc Teillaud

  122. Soluble Fcγ receptors II (FcγRII) are generated by cleavage of membrane FcγRII

    Article • European Journal of Immunology, January 1991, Wiley

    Dr Jean-Luc Teillaud

  123. Ion channels and b cell mitogenesis

    Article • Molecular Immunology, December 1990, Elsevier

    Dr Jean-Luc Teillaud

  124. Molecular and functional studies of recombinant soluble Fcγ receptors

    Article • Molecular Immunology, December 1990, Elsevier

    Dr Jean-Luc Teillaud

  125. Involvement of FcR+ T cells and of IGG-BF in the control of myeloma cells

    Article • Molecular Immunology, December 1990, Elsevier

    Dr Jean-Luc Teillaud

  126. Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells

    Article • Molecular Immunology, December 1990, Elsevier

    Dr Jean-Luc Teillaud

  127. Recombinant interleukin 2-activated natural killer cells regulate IgG2a production

    Article • European Journal of Immunology, August 1990, Wiley

    Dr Jean-Luc Teillaud

  128. Regulation of IgG production by suppressor FcγRII+ T hybridomas

    Article • European Journal of Immunology, January 1990, Wiley

    Dr Jean-Luc Teillaud

  129. FcγRII expression in resting and activated B lymphocytes

    Article • European Journal of Immunology, August 1989, Wiley

    Dr Jean-Luc Teillaud

  130. Immunoglobulin-binding factors

    Article • Immunology Letters, March 1989, Elsevier

    Dr Jean-Luc Teillaud

  131. Are Ts cells involved in isotype-specific regulation?

    Article • Research in Immunology, January 1989, Elsevier

    Dr Jean-Luc Teillaud

  132. Regulatory effects of IgG-BF on hybridoma B cells. Molecular characterization of variant cell lines

    Article • Molecular Immunology, November 1988, Elsevier

    Dr Christine Miossec, Dr Jean-Luc Teillaud

  133. Increased expression of Fcγ receptor in cancer patients and tumor bearing mice

    Article • Molecular Immunology, November 1988, Elsevier

    Dr Jean-Luc Teillaud

  134. Software for the quantitative evaluation of in vitro monoclonal antibody production from ELISA data

    Article • Journal of Immunological Methods, November 1987, Elsevier

    Dr Jean-Luc Teillaud

  135. Immunoglobulin G-binding factors (IgG-BF) inhibit IgG secretion by, as well as proliferation of, hybridoma B cells

    Article • Immunology Letters, November 1987, Elsevier

    Dr Jean-Luc Teillaud

  136. A sensitive method for testing the effect of immunoglobulin binding factor on Ig secretion by hybridoma B cells

    Article • Journal of Immunological Methods, February 1987, Elsevier

    Dr Jean-Luc Teillaud

  137. Heterogeneity of Murine IgG-Binding Factors (IgG-BF): Relation to Major Histocompatibility Complex Class II Antigens

    Article • January 1987, Elsevier

    Dr Jean-Luc Teillaud

  138. The Isotypic Circuit: Immunoglobulins, Fc Receptors and Immunoglobulin Binding Factors

    Article • International Reviews of Immunology, January 1987, Taylor & Francis

    Dr Jean-Luc Teillaud

  139. Molecular heterogeneity of murine IgG-BF

    Article • Molecular Immunology, November 1986, Elsevier

    Dr Jean-Luc Teillaud

  140. T Cell-derived Immunoglobulin-Binding Factors (IBF): Molecular Heterogeneity and Inhibition of Ig Synthesis by B Cell Hybridomas

    Article • January 1986, Elsevier

    Dr Jean-Luc Teillaud

  141. The Occurence, Structural and Functional Properties of Immunoglobulin Fc Receptors on Murine Neoplastic Cells

    Article • International Reviews of Immunology, January 1986, Taylor & Francis

    Dr Jean-Luc Teillaud

  142. The identification of monoclonal class switch variants by sib selection and an ELISA assay

    Article • Journal of Immunological Methods, November 1984, Elsevier

    Dr Jean-Luc Teillaud

  143. Monoclonal Antibodies: A Powerful Tool for Selecting and Analyzing Mutations in Antigens and Antibodies

    Article • Annual Review of Microbiology, October 1984, Annual Reviews

    Dr Jean-Luc Teillaud

  144. Molecular characterization of two Ia-like antigens in marmoset

    Article • Immunogenetics, January 1984, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  145. Monoclonal antibodies reveal the structural basis of antibody diversity

    Article • Science, November 1983, American Association for the Advancement of Science

    Dr Jean-Luc Teillaud

  146. Involvement of human membrane-associated complement components in the rosette formation between Marmoset red blood cells and human leukocytes

    Article • Cellular Immunology, January 1982, Elsevier

    Dr Jean-Luc Teillaud

  147. Analysis of DR-like molecules on a marmoset Epstein-Barr virus-induced cell line using a monomorphic anti-human HLA-DR monoclonal antibody

    Article • European Journal of Immunology, January 1982, Wiley

    Dr Jean-Luc Teillaud

  148. Monoclonal antibodies as a tool for phylogenetic studies of major histocompatibility antigens and ? 2-microglobulin

    Article • Immunogenetics, January 1982, Springer Science + Business Media

    Dr Jean-Luc Teillaud

  149. FcγR expressed on T-cell hybrids: Specificity, behavior and relationship with Ia antigens

    Article • Cellular Immunology, September 1981, Elsevier

    Dr Jean-Luc Teillaud

  150. Generation of Murine scFv Intrabodies from B-Cell Hybridomas

    Article • Springer Science + Business Media

    Dr Jean-Luc Teillaud

  151. Generation of scFv from a Phage Display Mini-Library Derived from Tumor-Infiltrating B-Cells

    Article • Springer Science + Business Media

    Dr Jean-Luc Teillaud